Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections June 3, 2022 Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 Is a Genomic Test Better at Finding Aggressive Prostate Cancer? October 13, 2022 ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ February 7, 2019 Load more HOT NEWS Can Topical Drugs Help Prevent Breast Cancer? Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... Lung Adenocarcinoma with Mucinous Histology ESMO Award for Immuno-Oncology 2025 Recipient Announced
